Korea, Switzerland Ink MOU To Combine Talents In Pharma, Medical Devices
This article was originally published in PharmAsia News
In a bid to bolster their respective health care industries, South Korea and Switzerland signed an MOU to cooperate on life sciences investments by combining Switzerland’s knowhow in precision machinery, nanotechnology and biotechnology with Korea’s expertise in manufacturing technology.
You may also be interested in...
SEOUL - Novartis signed a memorandum of understanding with Korea's Ministry for Health, Welfare and Family Affairs to invest $100 million (KRW 125 billion) over the next five years in the research and development of new drugs, scientific exchanges and collaboration in the life sciences
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.